Management of Endometrial Adenocarcinoma

Initial Diagnostic Workup

• The European Society of Gynaecological Oncology recommends obtaining tissue diagnosis through endometrial biopsy or dilation and curettage to confirm adenocarcinoma histology 1
• Pelvic MRI with dynamic contrast enhancement is the most accurate imaging modality to assess myometrial invasion depth and cervical stromal involvement 1
• Complete blood count, liver function tests, and renal function profiles should be ordered as part of preoperative evaluation, as recommended by the National Comprehensive Cancer Network 2, 1
• CA125 measurement may be considered, as levels >35 U/ml may predict extra-uterine disease extension, according to the Society of Gynecologic Oncology 1
• Transvaginal ultrasound should be obtained to evaluate endometrial thickness, myometrial invasion, and rule out ovarian involvement, as suggested by the American College of Obstetricians and Gynecologists 1
• CT chest/abdomen/pelvis or PET-CT should be requested for clinically advanced disease to assess for distant metastases, as recommended by the European Society of Medical Oncology 3, 4

Primary Surgical Management

• The American College of Surgeons recommends standard surgery consisting of total hysterectomy with bilateral salpingo-oophorectomy without vaginal cuff excision 3, 4, 1
• Minimally invasive surgery (laparoscopic or robotic) should be performed rather than laparotomy whenever possible, as it provides equivalent oncologic outcomes with superior perioperative benefits, according to the Society of Gynecologic Oncology 5, 1
• Systematic exploration, inspection, and palpation of the entire abdomen including liver, diaphragm, omentum, and peritoneal surfaces should be conducted, as recommended by the National Comprehensive Cancer Network 2, 1
• Peritoneal cytology should be obtained at the start of surgery, although it no longer affects FIGO staging, as suggested by the American Joint Committee on Cancer 5, 1
• Omentectomy should be performed for serous, clear cell, and carcinosarcoma histologies given increased risk of advanced-stage disease, according to the Society of Gynecologic Oncology 6

Risk Stratification and Adjuvant Therapy

• The National Comprehensive Cancer Network recommends observation alone without adjuvant therapy for low-risk disease (Stage IA, Grade 1-2, Endometrioid), with 5-year disease-free survival approximately 93% 1, 7
• Vaginal brachytherapy or observation alone may be chosen for intermediate-risk disease (Stage IB, Grade 1-2, Endometrioid), as recommended by the American College of Radiology 1
• External pelvic radiotherapy with or without vaginal brachytherapy boost, or vaginal brachytherapy alone, should be administered for high-risk early disease (Grade 3, Stage IB-IC), according to the European Society of Radiotherapy and Oncology 1
• Maximal surgical cytoreduction should be performed in patients with good performance status and advanced/metastatic disease (Stage III-IV), as recommended by the Society of Gynecologic Oncology 8
• Carboplatin/paclitaxel/trastuzumab triplet therapy should be used for HER2-positive uterine serous carcinoma or carcinosarcoma, as suggested by the National Comprehensive Cancer Network 1

Fertility-Sparing Management

• The American Society for Reproductive Medicine recommends referring young patients with Grade 1 endometrioid adenocarcinoma limited to the endometrium who desire fertility preservation to specialized centers 1
• Diagnosis should be confirmed through dilation and curettage by a specialist gynaecopathologist, which is superior to pipelle biopsy, according to the Society of Gynecologic Oncology 1
• Pelvic MRI should be performed to exclude myometrial invasion and adnexal involvement, as recommended by the European Society of Gynaecological Oncology 1
• Medroxyprogesterone acetate (400-600 mg/day) or megestrol acetate (160-320 mg/day) should be used for treatment, as suggested by the American College of Obstetricians and Gynecologists 1

Follow-Up Protocol

• The National Comprehensive Cancer Network recommends conducting history, physical, and gynecological examination every 3-4 months for the first 3 years, with extension of follow-up intervals to 6 months during years 4-5, and annual examinations thereafter 8, 7
• Focus should be on early detection of vaginal or pelvic relapses, which may be amenable to curative treatment, according to the Society of Gynecologic Oncology 8

Total Hysterectomy with Bilateral Salpingo‑Oophorectomy for Early‑Stage Low‑Grade Endometrioid Endometrial Carcinoma

Survival Outcomes

• Five‑year disease‑free survival of 93‑96 % and 15‑year overall survival up to 98 % for stage IA grade 1‑2 disease when treated with total hysterectomy + bilateral salpingo‑oophorectomy. (Evidence from large surgical series) [9][10]
• Five‑year overall survival of 93‑98 % across early‑stage low‑grade endometrioid carcinoma treated with this surgery, establishing it as the standard of care. (High‑quality cohort data) [9][11]

Disease Removal and Surgical Staging

• Occult adnexal metastases are found in 3‑11 % of clinically early‑stage cases, varying with tumor grade and depth of myometrial invasion; bilateral salpingo‑oophorectomy enables detection of these micrometastases. (Pathologic series) [9][12]
• Comprehensive surgical staging (direct abdominal inspection and palpation) identifies extra‑uterine disease, peritoneal implants, and lymph‑node involvement that imaging cannot reliably detect, guiding adjuvant‑therapy decisions. (Guideline‑based recommendation) [9][13]

Prevention Benefits

• Bilateral oophorectomy eliminates endogenous estrogen production, theoretically reducing stimulation of microscopic metastatic cells; however, a survival benefit from this hormonal effect has not been definitively proven. (Observational evidence) 9

Surgical Approach and Quality‑of‑Life

• Minimally invasive (laparoscopic or robotic) TH/BSO shortens hospital stay (≈52 % discharged ≤ 2 days vs 94 % with longer stays) and lowers moderate‑to‑severe postoperative complications (14 % vs 21 %). (Prospective cohort) [9][11]
• For low‑risk disease (stage IA grade 1‑2), surgery alone suffices; adjuvant radiation or chemotherapy is unnecessary, avoiding additional toxicity. (Evidence from surgical series) [9][10]
• The hysterectomy specimen provides definitive pathology (myometrial depth, cervical involvement, tumor size, lymph‑vascular space invasion, grade), essential for prognostication and treatment planning per NCCN guidelines. (Guideline recommendation) 14

Special Considerations

Ovarian Preservation in Selected Premenopausal Women

• In women < 45 years with grade 1 disease, < 50 % myometrial invasion, and no Lynch or BRCA mutation, ovarian preservation may be offered to avoid surgical menopause; SEER data show no overall‑survival decrement and a possible reduction in cardiovascular mortality. (Population‑based analysis) [9][13]11
• When ovaries are retained, concurrent bilateral salpingectomy is advised to mitigate future tubal cancer risk. (Consensus recommendation) 11

Lymphadenectomy Strategy

• Randomized trials demonstrate that systematic pelvic lymphadenectomy does not improve survival in apparent stage I disease; therefore, routine complete lymphadenectomy is not mandatory for low‑risk patients. (Level I evidence) 10
• Removal of suspicious nodes (minimum sampling) is recommended, with more extensive nodal assessment reserved for high‑risk features (grade 3, deep invasion, non‑endometrioid histology). (NCCN guideline) [9][13]

Fertility‑Sparing Option

• For highly selected young women desiring fertility, progestin therapy can be considered; durable complete response occurs in ~48 % of conservatively treated cases, underscoring the need for thorough counseling. (Prospective cohort) [9][14]

Surgical Approach Selection

• The LAP2 trial reported a 25.8 % conversion rate from minimally invasive to open laparotomy, highlighting the importance of surgeon expertise and appropriate patient selection. (Randomized trial) 11
• Obese patients derive particular benefit from robotic platforms, which reduce conversion and complication rates. (Subgroup analysis) 10